Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Y-mAbs Therapeutics Inc
Total Equity
Y-mAbs Therapeutics Inc
Total Equity Peer Comparison
Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors
Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
|
Total Equity
$99.2m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
$8B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$17.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$5B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-14%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$18.5B
|
CAGR 3-Years
27%
|
CAGR 5-Years
31%
|
CAGR 10-Years
31%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$27B
|
CAGR 3-Years
31%
|
CAGR 5-Years
23%
|
CAGR 10-Years
28%
|
See Also
What is Y-mAbs Therapeutics Inc's Total Equity?
Total Equity
99.2m
USD
Based on the financial report for Mar 31, 2024, Y-mAbs Therapeutics Inc's Total Equity amounts to 99.2m USD.
What is Y-mAbs Therapeutics Inc's Total Equity growth rate?
Total Equity CAGR 5Y
-5%
Over the last year, the Total Equity growth was -8%. The average annual Total Equity growth rates for Y-mAbs Therapeutics Inc have been -27% over the past three years , -5% over the past five years .